Literature DB >> 25090765

[Treatment of cervical cancer].

Cyril Touboul, Dounia Skalli, Eric Guillo, Michel Martin, Emmanuelle Mallaurie, Dhouha Mansouri, Issam Abd Al Samad, Naima Chabi, Sylvie Hospitel, Martin Koskas, Bassam Haddad.   

Abstract

The treatment of uterine cervical cancer evolved the last past twenty years. The management of early stages cervical cancer is based on surgery +/- after an initial brachytherapy in order to increase loco-regional control. A conservative treatment preserving uterine and ovarian functions is sometimes possible for young patients < 40 years old wishing to conceive. This strategy allows pregnancies with low recurrence rate. Finally, the use of the sentinel lymph node staging should be validated within the next few years. The treatment of locally advanced stages is based on concomitant chemoradiation therapy, which allows obtaining an important complete tumour response rate (90%). Thereafter, the irradiation modalities will depend on the para-aortic lymph nodes status diagnosed by PET-computed tomography +/- staging laparoscopic para-aortic lymphadenectomy. The use of completion surgery may be indicated in case of cervical residual disease and has to be balanced with its specific morbidity. All the decisions are made during a multidisciplinary tumour board.

Entities:  

Mesh:

Year:  2014        PMID: 25090765

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  2 in total

1.  Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.

Authors:  Liqiong Cai; Zehua Wang; Denghua Liu
Journal:  Tumour Biol       Date:  2015-12-02

2.  lncRNA OIP5-AS1 targets ROCK1 to promote cell proliferation and inhibit cell apoptosis through a mechanism involving miR-143-3p in cervical cancer.

Authors:  Linlin Song; Linlin Wang; Xiaoli Pan; Caihong Yang
Journal:  Braz J Med Biol Res       Date:  2020-01-13       Impact factor: 2.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.